Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
A lab-on-a-chip platform for integrated extraction and detection of SARS-CoV-2 RNA in resource-limited settings

Pablo Rodriguez-Mateos a, Bongkot Ngamsom a, Cheryl Walter b, Charlotte E. Dyer b, Jesse Gitaka c, Alexander Iles a, Nicole Pamme a, *

a Department of Chemistry and Biochemistry, University of Hull, UK
b Department of Biomedical Sciences, University of Hull, UK
c Directorate of Research and Innovation, Mount Kenya University, Thika, Republic of Kenya

Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the unprecedented global pandemic of coronavirus disease-2019 (COVID-19). Efforts are needed to develop rapid and accurate diagnostic tools for extensive testing, allowing for effective containment of the infection via timely identification and isolation of SARS-CoV-2 carriers. Current gold standard nucleic acid tests require many separate steps that need trained personnel to operate specialist instrumentation in laboratory environments, hampering turnaround time and test accessibility, especially in low-resource settings. We devised an integrated on-chip platform coupling RNA extraction based on immiscible filtration assisted by surface tension (IFAST), with RNA amplification and detection via colorimetric reverse-transcription loop mediated isothermal amplification (RT-LAMP), using two sets of primers targeting open reading frame 1a (ORF1a) and nucleoprotein (N) genes of SARS-CoV-2. Results were identified visually, with a colour change from pink to yellow indicating positive amplification, and further confirmed by DNA gel electrophoresis. The specificity of the assay was tested against HCoV-OC43 and H1N1 RNAs. The assay based on use of gene N primers was 100% specific to SARS-CoV-2 with no cross-reactivity to HCoV-OC43 nor H1N1. Proof-of-concept studies on water and artificial sputum containing genomic SARS-CoV-2 RNA showed our IFAST RT-LAMP device to be capable of extracting and detecting 470 SARS-CoV-2 copies mL⁻¹ within 1 h (from sample-in to answer-out). IFAST RT-LAMP is a simple-to-use, integrated, rapid and
1. Introduction

An outbreak of Coronavirus Disease 2019 (COVID-19) caused by a novel human betacoronavirus SARS-CoV-2 was reported in Wuhan, Hubei province of China, in late December 2019 [12]. Due to the rate of transmission and possible fatal progression, the World Health Organisation (WHO) declared a global health emergency on 31 January 2020 and a pandemic situation on 11 March 2020 [3]. The clinical spectrum of COVID-19 ranges from asymptomatic infection to acute respiratory distress syndrome with multisystem failures [4,5]. The epidemiological update as of 4 February 2021 reported over 100 million cumulative cases and 2.2 million deaths globally since the start of the pandemic [6]. The increasing gravity of the situation has been attributed to the highly contagious nature of the disease from both asymptomatic and pre-symptomatic cases [7,8], in combination with the lack of effective point-of-care testing for rapid and accurate identification of SARS-CoV-2 carriers [9].

Among rapid diagnostic tests developed for point-of-care and community purposes are the antigen lateral flow tests targeting the nucleocapsid protein of SARS-CoV-2. Despite showing great promise for ease-of-use and <30 min turnaround time, the low sensitivity (10⁶ copies ml⁻¹) is a major disadvantage of this approach [10]. Current gold standard COVID-19 diagnostic tests still rely on nucleic acid amplification tests measuring viral nucleic acids based on quantitative reverse transcription polymerase chain reaction (RT-qPCR). Samples from the upper respiratory tract (nasopharyngeal swab, nasal aspirate, or pharyngeal swab) or lower respiratory tract (sputum, tracheal aspirate) are taken from suspected cases for RNA extraction followed by reverse transcription and cDNA amplification of a genomic specific region [4,5]. The analytical limits of detection of RT-qPCR are usually around 10² viral RNA copies ml⁻¹ with sample-to-result times of 24–48 h [11]. Several SARS-CoV-2 RT-PCR detection kits have been developed by different companies and institutions [9]. However, such assays are mostly limited to highly specialized laboratories with trained personnel [4,12]. As opposed to conventional PCR assays, isothermal nucleic acid amplification tests utilise a single temperature and involve no expensive instrumentation, requirement for calibrated internal controls nor trained personnel for operation and result interpretation. Specifically, loop-mediated isothermal amplification (LAMP) relies on auto-cycling strand displacement DNA synthesis using four to six primers, resulting in exponential amplification [13]. Colorimetric RT-LAMP based on pH change can offer rapid and sensitive detection of viral RNAs and requires only a heat source [14,15]. RT-LAMP has been applied for detection of many viral infectious diseases [15]. Several groups have explored RT-LAMP for SARS-CoV-2 RNA detection, showing comparable results to the gold standard RT-PCR with lowest sensitivity being ca. 20–200 RNA copies per reaction, while achieving faster turnaround times (30–40 min) [16–22]. Despite the successful detection of SARS-CoV-2 RNA from crude cell lysates reported by Zhang et al. [16], the majority of the reported RT-LAMP assays required RNA extraction and purification steps to be performed on clinical samples prior to amplification using laboratory based techniques and procedures. A lower sensitivity of the assays was also reported when clinical samples were directly subjected to RT-LAMP without an RNA isolation step [23]. In addition, investigations on direct RT-LAMP of respiratory samples without RNA extraction using the Variplex™ system [24] demonstrated high false negative rates as well as failure to reliably detect SARS-CoV-2 [25].

A lab-on-a-chip process for a combined workflow of nucleic acid extraction and purification, namely ‘IFAST’, utilises ‘pinned’ aqueous/organic liquid interfaces in microchannels to streamline the extraction mechanism, replacing all washing steps with a single traverse of an immiscible fluid barrier [26]. By attaching magnetically-responsive particles to a target cell/molecule via immunocapture, the target bound magnetic particles can be selectively transported across the immiscible barrier and into a separate solution. Contaminants are prevented from inadvertently crossing the immiscible phase by the high interfacial energy associated with the immiscible phase/aqueous phase boundaries [27]. IFAST has been successfully employed for preconcentration and purification of DNAs [26,28,29] and RNAs [29,30] from various samples. The platform is simple and requires no additional laboratory infrastructure, and yet maintains comparable or better purity, yield and scalability to existing methods [26]. Previously, our group combined the versatility of the IFAST device with sensitive molecular detection via adenosine triphosphate (ATP) bioluminescence assay, and devised on-chip IFAST/ATP platforms for rapid detections of Escherichia coli O157:H7 from wastewater samples [31], and Group B Streptococcus from urine samples [32] for point-of-need testing in resource-limited settings. Very recently, Wimbles et al. reported the use of IFAST RT-LAMP platform for on-site extraction of DNA from animal dung, enabling identification of Ceratotherium simum, a near-threatened species [33].

In this communication, we present for the first time, a lab-on-a-chip device based on IFAST RT-LAMP for rapid detection of genomic SARS-CoV-2 RNAs, integrating consecutive steps of (I) RNA extraction, (II) purification and (III) amplification (RT-LAMP) with colorimetric readout for qualitative result interpretation (Fig. 1). The platform permits simple identification of SARS-CoV-2 infection via the naked eye, fast turnaround from sample-in to answer-out (within 1 h) and requires only chip loading and manipulation of magnetic particles that can be performed by minimally trained staff, enabling widespread screening of the infection for optimised prevention and treatment at the point of care in low-resource settings.

2. Materials and methods

2.1. Reagents

Genomic SARS-CoV-2 RNA (2019-nCoV/USA-WA1/2020, ATCC VR-1986D), HCoV-OC43 (ATCC VR-1558D) and H1N1 (ATCC VR-1736D) were purchased from LGC standards, UK. WarmStart® DNA and RNA polymerase (MS1800S) was purchased from New England Biolabs. Primers were purchased from Integrated DNA Technologies (IDT). Oligo (dT)-coated magnetic beads, SYBR Safe and nuclease-free water were supplied by Thermofisher Scientific, UK. Mineral oil and guanidine hydrochloride (GuHCl) were purchased from Sigma-Aldrich.
2.2. Chip design, fabrication and preparation

This work utilised polymethyl methacrylate (PMMA) chips fabricated via CNC machine milling (Datron M7, Milton Keynes, UK), rather than the polydimethylsiloxane (PDMS) chips employed previously for IFAST/ATP platforms [31,32]. The chip features a large sample chamber 1 (26 mm wide, 26 mm long); wash chambers 2, 4, 6 (3 mm wide × 3 mm long); wash chamber 3 (3 mm wide × 14 mm long); wash chambers 5, 7, 8 (3 mm wide × 8.5 mm long); and a detection chamber 9 (3 mm wide × 3 mm long). All chambers used had a depth of 3.8 mm, and were interconnected via gates (3 mm to 0.5 mm wide, 3 mm long, 0.2 mm deep) as shown in Fig. 2. To reduce carry-over and provide more effective washing, the previous chip designs were modified to include more wash chambers (Section B, Supplementary Data). To prevent contamination with RNases, devices were sprayed with RNase decontamination solution (ThermoFisher Scientific), followed by rinsing with nuclease-free water and were left to dry prior to use. The bottom of the chip was sealed with PCR adhesive film (ThermoFisher Scientific).

2.3. RT-LAMP

Tube-based RT-LAMP was firstly performed targeting ORF1a and N genes using two sets of primers as described by Zhang et al., (Table S1, Supplementary Data [16]). Ten-fold serial dilutions of genomic SARS-CoV-2 RNA (4.7 × 10^6 copies mL^-1) were performed in nuclease-free water. The tube-based RT-LAMP reaction was conducted with the following composition: 16 μM forward inner primer (FIP) and backward inner primer (BIP), 2 μM forward outer primer (F3) and backward outer primer (B3), 4 μM forward loop primer (LF) and backward loop primer (LB), 1X LAMP reaction mix, 1 μL of the target RNA, and nuclease-free water to make up to a final volume of 20 μL. RT-LAMP products were electrophoresed in 1% w/v agarose gels stained with SYBR Safe at 80 V for 45 min. Gels were imaged in a molecular imager (Chemidoc XRS+, BioRAD). The specificity of the assay was tested by replacing the genomic SARS-CoV-2 RNA with equal volumes of genomic HCoV-OC43 or H1N1 RNAs. RT-LAMP of HCoV-OC43 and H1N1 RNAs with their respective primers (Tables S2 and S3, Supplementary Data) were employed for positive amplifications. Colour was visible directly on removal from incubation temperature. However, the reaction was cooled to room temperature to allow colour intensification prior to photographing. Tubes or IFAST devices were placed on an A4 white printing paper to provide a clear background. Images were captured using a mobile phone camera (SAMSUNG Galaxy A3) taken from above the tubes/IFAST devices, under normal laboratory lighting. For comparison, images of tube/IFAST device with negative control were taken in the same frame as the investigated samples.

For on-chip RT-LAMP, the PMMA chambers were alternately filled with aqueous solutions (chambers 1, 3, 5, 7) and mineral oil (chambers 2, 4, 6, 8). RT-LAMP reaction mix was prepared in a PCR tube (20 μL; 8 μL H2O, 2 μL of primer mix and 10 μL of RT-LAMP MasterMix) and added to detection chamber 9 overlaying with 10 μL mineral oil to prevent evaporation during LAMP. The device was placed on a pre-warmed block heater (SBH200D, Stuart) set at 65 °C for 30–45 min. Visualisation of colour change of the solution in chamber 9 was employed for result verification prior to gel.

Fig. 1. Conceptual scheme for the microfluidic IFAST RT-LAMP device for SARS-CoV-2 RNA detection comprising three consecutive steps: (I) RNA extraction via oligo (dT)-functionalised magnetic beads; (II) separation and purification of magnetic bead-captured RNA through a series of immiscible liquids; and (III) colorimetric RT-LAMP for detection of extracted RNA. Visible change of colour from pink to yellow indicates SARS-CoV-2 positive. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Fig. 2. (a) Design of the IFAST RT-LAMP device featuring a sample chamber (1) interconnected to wash chambers (2–8) and detection chamber (9) via gates. (b) Photograph of an IFAST RT-LAMP microfluidic device for SARS-CoV-2 RNA detection.
2.4. On-chip RNA extraction

For RNA extraction in the IFAST devices, 1 μL of RNA at the corresponding dilution was added to 999 μL nuclease-free water containing Tween 20 (final concentration = 0.005% w/v, to prevent oligo (dT)-coated magnetic beads (MB) from sticking to the adhesive tape used to seal the bottom of the device) in the sample chamber. Subsequently, 20 μL of MB were added and the device was either manually agitated or placed on a rotator (SB3, Stuart) at 40 rpm for 10 min. Afterwards, the downstream chambers 2, 4 and 6 were filled with mineral oil, and chambers 3, 5 and 7 with 0.005% Tween 20. Collection of RNA-bound MB from the sample chamber was achieved by placing a neodymium iron boron (NdFeB) magnet assembly at the bottom of the chip [31]. The assembly featured a 4 mm diameter × 2 mm height disc magnet and a 20 mm × 10 mm × 5 mm bar magnet (Magnet Sales, UK), providing a magnetic strength of 0.4 T. Washing of MB was then carried out by dragging the beads through the aqueous/oil barriers and briefly storing in chamber 7. The magnetically isolated RNA in 0.005% Tween 20 was pipetted from chamber 7 into a PCR tube where RT-LAMP was to be performed to verify successful magnetic isolation of RNA from the on-chip extraction. After removing the supernatant, the beads with captured RNA were resuspended in 20 μL of LAMP reaction mix and incubated in a block heater set at 65 °C for 30–40 min.

2.5. Integrated on-chip RNA extraction and on-chip RT-LAMP

On-chip RNA extraction was similarly performed as described above, followed by the addition of LAMP mix (20 μL) in chamber 9 into which the RNA-captured beads were mixed and the chamber overlaided with 10 μL mineral oil. The chip was placed on a block heater for RT-LAMP at 65 °C for 40 min. The complete workflow is demonstrated in Section E, Supplementary Data. A similar process was carried out with artificial sputum samples spiked with genomic RNAs, except that the 0.005% w/v Tween 20 was replaced with sputum samples formulated according to Kaur et al. [34]. To prepare a negative control of RNA-spiked samples, artificial sputum (250 μL) was spiked with HCoV-OC43 (1 μL, 5 pg μL⁻¹) and H1N1 (1 μL, 0.029 ng μL⁻¹) genomic RNAs and the mix was directly added to the sample chamber of the device. The positive sample was prepared similarly to the negative control, except that the sample was also spiked with 1 μL of 0.095 ng μL⁻¹ SARS-CoV-2 RNA to afford a final concentration of 470 SARS-CoV-2 copies μL⁻¹. RNA-spiked artificial sputum was diluted with 748 μL of 5 M GuHCl (final concentration = 3.7 M) and 2 μL of 2.5% w/v Tween 20 (final concentration = 0.005% w/v) inside the sample chamber. On-chip processes were subsequently performed as described above for the SARS-CoV-2 spiked water samples. The full workflows were independently tested by two operators.

3. Results and discussion

3.1. On-chip RT-LAMP for genomic SARS-CoV-2 RNA detection

Utilising the commercially available colorimetric LAMP kit and two primer sets targeting ORF1a and N genes [16], the effectiveness of tube-based RT-LAMP for SARS-CoV-2 RNA detection was firstly assessed on a series of ten-fold dilutions performed on the initial genomic RNA (4.7 × 10⁴ copies μL⁻¹). The assay was capable of amplifying ≥470 copies of genomic RNA after 30 min (Fig. 3), a reduced sensitivity compared with 120 copies being reported for RNA fragments using the same primer sets reported by Zhang et al. [16]. Being amongst the largest viral genomes, with 30 kb size [35], a longer time is expected for primers and enzymes to find the target sequences within the genome compared with much shorter RNA fragments.

In order to check the feasibility of performing on-chip RT-LAMP as a consecutive step after RNA extraction, it is vital to verify that (i) on-chip amplification occurs similarly to the tube-based assay, and (ii) the magnetic beads utilised for RNA extraction do not interfere with amplification. Consequently, for on-chip RT-LAMP, oligo (dT)-functionalised magnetic beads were added to the sample chamber and directed through the immiscible phases to combine with the RT-LAMP reaction mix in the last chamber prior to heating. Successful on-chip amplification was achieved with no interference from the magnetic beads.
3.2. Specificity of RT-LAMP assays for SARS-CoV-2 detection

The specificity of the RT-LAMP primers for SARS-CoV-2 RNA detection was tested against Betacoronavirus HCoV-OC43, a ubiquitous human coronavirus in the environment responsible for up to one third of common colds [36,37], and influenza A virus H1N1, which shares substantial similarities in viral shedding, transmission dynamics and clinical features of viral respiratory illnesses [38]. RT-LAMP assays conducted on genomic HCoV-OC43 and H1N1 RNAs using corresponding primers showed positive amplifications (Fig. 4a).

Although demonstrating a slightly faster amplification than Gene N primers, ORF1a primers showed cross-reactivity with both HCoV-OC43 and H1N1 RNAs (Fig. 4b) explained by sequence similarity, and were excluded from further investigations. In contrast, only samples with SARS-CoV-2 RNA resulted in positive amplifications exploiting Gene N primers, while HCoV-OC43 and H1N1 remained negative (Fig. 4b and c), demonstrating specific pairing of Gene N primers to SARS-CoV-2 RNA, but not to HCoV-OC43 or H1N1 RNAs. This indicates the possibility of simultaneously diagnosing infection(s) of COVID-19 (SARS-CoV-2), a common cold virus (HCoV-OC43), and influenza A virus (H1N1) by paralleling on-chip RT-LAMP at a single amplification temperature and time, using primer sets specific to target viral genomes.

3.3. On-chip SARS-CoV-2 RNA extraction via IFAST

The microscale IFAST was next explored as a platform for one-step isolation and purification of SARS-CoV-2 RNA. Typically, multi-step solid phase extraction (SPE) processes for RNA extraction (e.g., Qiagen TurboCapture, Invitrogen FastTrack MAG 96) are labour-intensive and require expensive automated systems to facilitate the extensive washing that must be performed on individual samples [26]. The IFAST approach simplifies and expedites the cumbersome RNA extraction process, and enables direct interfacing with the amplification process, reducing overall labour and time-consuming pre-amplification steps. Oligo (dT)-function-alised magnetic beads were employed for selective isolation of polyadenylated RNA species. This specific capture discriminates ribosomal RNA, DNA, proteins and small RNA molecules. Although RNA fragmentation may occur during extraction, primers targeting the N gene region near to the 3′ poly-A tail were used to ensure that the captured genome region could be amplified and detected. One further advantage of using oligo (dT) magnetic beads is that this approach can also provide an opportunity to include a positive swab control, such as detection of RNase P mRNA [39]. This abundant mRNA is an excellent sample control that is currently a typical internal standard for RT-PCR diagnostics, but is not incorporated in point-of-care COVID-19 lateral flow testing devices [40,41].

The successful use of IFAST was demonstrated for extraction and purification of genomic SARS-CoV-2 RNA from aqueous samples containing 470 copies mL⁻¹ within 10 min, validated by positive amplification of bead-bound isolated RNA via off-chip RT-LAMP assays (Fig. 5). In these experiments, the magnetically isolated RNAs would be between 470 and 47 copies, as suggested by Fig. 3 (the same reaction time amplified 470 copies, Gene N primers). The level of detected genomic RNA isolated on-chip was significantly lower than the reported median viral loads of 7.99 × 10⁴ copies mL⁻¹ and 7.52 × 10⁵ copies mL⁻¹ in throat swab and sputum samples, respectively [42]. This on-chip IFAST purification process uses only minute quantities of mineral oil that can effectively filter contaminants from clinical samples in a single step, thereby eliminating multiple washing or centrifugation steps normally needed for RNA purification. The positive amplifications of the magnetically-isolated RNA by off-chip RT-LAMP confirmed successful purification with no adverse effect on RNA integrity. The current protocol was performed manually, demonstrating its simplicity with no requirement for additional laboratory infrastructure. However, improved capacity can be achieved by automation [43]. This on-chip RNA extraction platform is not limited by the use of oligo (dT) magnetic beads, it can also be applied with other suitable surface chemistries for magnetic isolation, e.g., silica paramagnetic particles [30,33,44], and can be further explored for RNA extraction from clinical samples.

3.4. On-chip integration of RNA extraction and detection via IFAST RT-LAMP for detection of SARS-CoV-2 RNA

Having shown the two on-chip processes separately, i.e. RNA extraction via IFAST and RT-LAMP, the combined workflow for on-chip extraction and on-chip RT-LAMP was next investigated with water samples containing genomic RNA (Fig. 6a). The platform was capable of detecting 470 RNA copies from 1 mL sample in 40 min. The entire process took less than 1 h to complete (2 min sample loading, 10 min RNA extraction and 40 min amplification), with the negative/positive results being clearly distinguishable by the naked eye.

The performance of the platform was further tested with artificial sputum spiked with genomic RNAs due to clinical sample inaccessibility during the investigation. The device is ultimately aimed for point-of-care testing, with swab samples being directly loaded into the sample chamber to mix with lysis reagents, followed by RNA extraction, amplification and visual detection for negative/positive results. With this in mind, the RNA-spiked artificial sputum samples were diluted with GuHCl, a chaotropic reagent commonly used for isolation of intact mRNA from cells [45], as lysis buffer containing strong surfactant can destroy the immiscible interfaces of the IFAST device. In addition, GuHCl can act as a ribonuclease (RNase) inhibitor which helps to maintain RNA integrity, a common challenge in analysis of clinical samples. By using GuHCl, mRNAs could be isolated from potential viral capsids without any additional steps, extracted with oligo (dT) magnetic beads and amplified via RT-LAMP. The compatibility of the GuHCl with RNA extraction by oligo (dT) magnetic beads, as well as RT-LAMP, was shown by successful specific detection of SARS-CoV-2 from samples containing SARS-CoV-2, H1N1 and HCoV-OC43 RNAs (Fig. 6b). This demonstrates the feasibility of implementing the platform with patient samples; clinical validation will be conducted in Kenya when COVID-19 travel restrictions are lifted.

We delivered a proof-of-concept IFAST RT-LAMP platform for detection of genomic SARS-CoV-2 from water and artificial sputum samples, integrating RNA extraction and colorimetric RT-LAMP in one device. This lab-on-a-chip platform offers a ≤1 h turnaround time exploiting a single device that includes all essential steps required for rapid, sensitive and specific detection of SARS-CoV-2 RNA. This qualitative technology with distinct colour change from pink (negative) to yellow (positive) can be easily visualised under normal ambient light conditions. At the current proof-of-concept stage, all samples and reagents are manually pipetted into the device. Nevertheless, we anticipate pre-storage of immiscible liquids in wash chambers as well as lyophilised RT-LAMP reagents for the ready-to-use device. This would reduce the number of required pipetting steps where end users would only introduce the sample and magnetic beads, making the platform more deployable for point-of-care testing.

The present setup successfully isolated and detected 470 copies of genomic SARS-CoV-2 from 1 mL sample in 60 min; a superior sensitivity to the 4 × 10³ copies mL⁻¹ reported from the iAMP® COVID-19 Detection Kit [9]. Other small footprint rapid test
Fig. 4. Specificity investigations: (a) Tube-based RT-LAMP assays of HCoV-OC43 and H1N1 RNAs with their respective primers. (b) RT-LAMP assays of SARS-CoV-2, HCoV-OC43 and H1N1 RNAs using ORF1a and Gene N primers. (c) RT-LAMP assays using Gene N primers: 1 = no template control, 2 = HCoV-OC43 + H1N1 RNAs, and 3 = SARS-CoV2 + HCoV-OC43 + H1N1 RNAs. All assays performed at 65 °C for 30 min; HCoV-OC43 = 0.005 ng, H1N1 = 0.0289 ng, and SARS-CoV-2 = 0.095 ng (n = 3).
The equipment being developed for the point-of-care diagnosis of COVID-19 include the ID NOW™ COVID-19 Test Kit (Food and Drug Administration under Emergency Use Authorizations, Abbott), and microchip RT-PCR COVID-19 detection kit (Luminex). Despite achieving the excellent ≤13 min turnaround time, with minimal reagent consumption, diminished contamination and occasional human errors, special instrumentation is still required for result interpretation. Additionally, these platforms have lower sensitivities ($2 \times 10^4$ and $9 \times 10^3$ copies mL$^{-1}$, for Abbott and Luminex systems, respectively) compared to conventional RT-qPCR [46].
herein proposed RNA-based platform is also much more sensitive than rapid antigen-based lateral flow assays aiming for community and point-of-care testing, whose positive results normally require confirmation from nucleic acid amplification test(s) [9,47].

The cost of our device is currently ca. $10 (small scale device fabrication = $1.8, reagents = $8.3; the FDA EUA approved Abbott BinaxNOW™ COVID-19 Ag Card rapid test costs $5). This estimation excluded the cost of a block heater and NdFeB magnet assembly as they can be reused. This figure is anticipated to be substantially reduced by mass production, i.e., using injection moulding process to replace the CNC-machined fabrication.

4. Conclusion

We have devised a low complexity, high sensitivity and specificity lab-on-a-chip platform based on IFAST RT-LAMP for SARS-CoV-2 RNA detection, integrating two consecutive steps of RNA extraction and amplification into a single device. The current setup allowed detection of as little as 470 copies of genomic RNA within 1 h. This platform has the potential to increase COVID-19 screening speed and expand testing capacity for disease surveillance as well as point-of-care testing in resource-limited settings, enabling timely isolation prior to unwitting viral transmission.

CRediT authorship contribution statement

Pablo Rodriguez-Mateos: Conceptualization, Validation, Investigation, Formal analysis, Visualization, Writing – original draft, Writing – review & editing.
Bongkot Ngamsom: Conceptualization, Validation, Investigation, Formal analysis, Visualization, Writing – original draft, Writing – review & editing.
Cheryl Walter: Conceptualization, Supervision, Writing – review & editing.
Charlotte E. Dyer: Conceptualization, Funding acquisition, Supervision, Writing – review & editing.
Alexander Iles: Conceptualization, Funding acquisition, Supervision, Writing – review & editing.
Nicole Pamme: Conceptualization, Funding acquisition, Supervision, Writing – review & editing.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.

Acknowledgement

This work was supported by the European Union’s Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie Grant Agreement Number 765042, and the Community for Analytical Measurement Science (CAMS) - https://cams-uk.co.uk | @CAMs_UK | www.linkedin.com/company/cams-uk |
subpopulations via immiscible filtration assisted by surface tension (IFAST), Biomed. Microdevices 13 (2011) 1033–1042.

[28] L. Strotman, G. Lin, S. Berry, E. Johnson, D. Beebe, Facile and rapid DNA extraction and purification from food matrices using IFAST (immiscible filtration assisted by surface tension), Analyst 137 (2012) 4023–4028.

[29] L. Strotman, R. O’Connell, B. Casavant, S. Berry, J. Spenger, J. Lang, D. Beebe, Selective nucleic acid removal via exclusion (SNARE): capturing mRNA and DNA from a single sample, Anal. Chem. 85 (2013) 9764–9770.

[30] S.M. Berry, A.J. LaVanway, H.M. Pezzi, D.J. Guckenberger, M.A. Anderson, J.M. Loeb, D.J. Beebe, HIV viral RNA extraction in wax immiscible filtration assisted by surface tension (IFAST) devices, J. Mol. Diagn. 16 (2014) 297–304.

[31] B. Ngamsom, A. Truyts, L. Fourie, S. Kumar, M. Tarn, A. Iles, K. Moodley, K. Land, N. Pamme, A microfluidic device for rapid screening of E coli O157:H7 based on IFAST and ATP bioluminescence assay for water analysis, Chemistry-a European Journal 23 (2017) 12754–12757.

[32] B. Ngamsom, E. Wandera, A. Iles, R. Kimani, F. Muregi, J. Gitaka, N. Pamme, Rapid detection of Group B Streptococcus (GBS) from artificial urine samples based on IFAST and ATP bioluminescence assay: from development to practical challenges during protocol testing in Kenya, Analyst 144 (2019) 6889–6897.

[33] R. Wimbles, L.M. Melling, B. Cain, N. Davies, J. Doherty, B. Johnson, K.J. Shaw, On-site genetic analysis for species identification using lab-on-a-chip, Ecol. Evol. (2020) 1–9.

[34] N. Kaur, J. Michael, B. Toley, A modular paper-and-plastic device for tuberculosis nucleic acid amplification testing in limited-resource settings, Sci. Rep. 9 (2019).

[35] R.A. Khailany, M. Safdar, M. Ozaslan, Genomic characterization of a novel SARS-CoV-2, Gene Rep 19 (2020) 100682.

[36] J. St-Jean, H. Jacomy, M. Desforges, A. Vabret, F. Freemuth, P. Talbot, Human respiratory coronavirus OC43: genetic stability and neuroinvasion, J. Virol. 78 (2004) 8824–8834.

[37] B. Chen, E. Tian, B. He, L. Tian, R. Han, S. Wang, Q. Xiang, S. Zhang, T. El Arnaout, W. Cheng, Overview of lethal human coronaviruses, Signal Transduction and Targeted Therapy (2020) 5.

[38] P. Li, Y. Wang, M.P. Peppelenbosch, Z. Ma, Q. Pan, Systematically comparing COVID-19 with the 2009 influenza pandemic for hospitalized patients, Int. J. Infect. Dis. 102 (2021) 375–380.

[39] Y.N.H. Hospital, ACCELERATED EMERGENCY USE AUTHORIZATION (EUA) SUMMARY SARS-CoV2 RT-PCR Assay, 2020.

[40] L.M.G. Inc., Innova: SARS-CoV-2, Antigen Rapid Qualitative Test, 2020.

[41] C. AccessBio, Carestart COVID-19 Antigen: Rapid Diagnostic Test for the Detection of SARS-CoV-2 Antigen, 2020.

[42] Y. Pan, D. Zhang, P. Yang, L. Poon, Q. Wang, Viral load of SARS-CoV-2 in clinical samples, Lancet Infect. Dis. 20 (2020) 411–412.

[43] S.M. Berry, K.J. Regehr, B.P. Casavant, D.J. Beebe, Automated operation of immiscible filtration assisted by surface tension (IFAST) arrays for streamlined analyte isolation, J. Lab. Autom. 18 (2013) 206–211.

[44] O. Mosley, L. Melling, M. Tarn, C. Kemp, M. Esfahani, N. Pamme, K. Shaw, Sample introduction interface for on-chip nucleic acid-based analysis of Helicobacter pylori from stool samples, Lab Chip 16 (2016) 2108–2115.

[45] R.E. Farrells, RNA Methodologies: A Laboratory Guide for Isolation and Characterization, fourth ed. ed., AP Academic Press, 2010.

[46] A. Afzal, Molecular diagnostic technologies for COVID-19: limitations and challenges, J. Adv. Res. 26 (2020) 149–159.

[47] CDC Coronavirus Antigen Test Guidelines, 2020.